Vaccine Delivery Devices Market Size, Share & Trends Analysis Report By Device, By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global vaccine delivery devices market size was valued at USD 6,449.8 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.5% from 2023 to 2030. Growing immunization programs and their increasing coverage, development of novel vaccines, various campaigns and initiatives, growing research in the field of vaccination, and increasing government support and investment are some of the key factors that are contributing to the growth of the market. Biotech and pharmaceutical companies in partnership with governments across the globe are working towards the strategy for supply network disruptions in vaccine delivery and the development of effective vaccinations. The urgency to locate and oversee a COVID-19 vaccine has generated interest in providing an effective and safe viral delivery system, or preferably, multiple delivery systems.

In January 2022, to facilitate the urgency of transforming vaccine doses into protected and vaccinated communities, UNICEF, Gavi, and the WHO launched the COVID-19 Vaccine Delivery Partnership (CoVDP). The partnership was aimed at providing immediate operational support to 34 countries that had 10% or below vaccination coverage. Overall, the partnership targeted vaccine delivery and supply chain management for 92 countries. Increasing demand for the treatment of hepatitis A and B, meningitis, and influenza has propelled the market growth. Additionally, the global surge in demand for COVID-19 vaccination provided a significant opportunity for the market. Overall, the COVID-19 epidemic had a positive impact on the market and is expected to further fuel growth due to the introduction of booster vaccination doses.

Increasing research and investment in the development of vaccines is also one of the key drivers of the market. The Canadian Institutes of Health Research Institute of Infection and Immunity supports and funds research activities aimed at reducing the burden of infectious diseases, allergies, and immune-mediated diseases. The institute invests around USD 1 million per year to support the research of hepatitis C, USD 45.7 million through partnerships for pandemic influenza research, and USD 22.5 million to support the CIHR HIV/AIDS Research Initiative.

Furthermore, technological advancements for the efficient delivery of vaccines are expected to propel market growth. The need for needle-free delivery of these products has risen owing to needle stick injuries, risk of infections due to the reuse of needles, and transmission of blood-borne infections due to improper sterilization of needles. The growing interest of key players and various international organizations and institutions in novel delivery technologies is also expected to drive the market in the future. For instance, in January 2022, Pfizer Inc. and Acuitas Therapeutics entered into a strategic partnership agreement to collaborate on the development of a lipid nanoparticle delivery system designed specifically for mRNA vaccines and therapeutics. This collaboration aims to leverage the expertise of both companies to enhance the delivery efficiency and effectiveness of mRNA-based treatments and vaccines.

Device Insights

The syringes segment accounted for the largest revenue share of 87.2% in 2022. Syringes are commonly used to administer vaccines. They are largely used in routine immunization and mass vaccination programs as they are inexpensive and effective. Novel and technologically advanced syringes such as auto-disposable syringes and prefilled syringes are gaining popularity.

However, many people have a phobia of needles used in syringes because of the pain caused by them. Improper sterilization of needles and their reuse increases the risk of various infections. Thus, auto-disable syringes, which are safe and meant for single use, are being widely used in immunization campaigns. Adoption of prefilled syringes is also increasing due to various advantages associated with their usages such as operational efficiency, minimized vaccine wastage, and improved patient safety.

Route of Administration Insights

The intradermal vaccination segment accounted for the largest revenue share of 62.7% in 2022. This route of vaccine delivery has attracted interest in the past few years owing to benefits such as dose sparing, improved safety, and improved access to vaccines. These factors are expected to contribute to the growth of this segment over the following years. Furthermore, an increase in the studies of alternative methods for intradermal administration with novel devices such as jet injectors and microneedles is anticipated to drive the segment.

The intramuscular vaccination material segment is estimated to register the fastest CAGR of 7.9% over the forecast period. The majority of vaccines are administered through the intramuscular route. Delivery through this route reduces adverse reactions at the injection site. Intramuscular injections are widely adopted because they deliver medications deep inside muscle tissues, which results in quick absorption.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 32.1% in 2022. Growing immunization coverage, increasing investments in R&D for new vaccines, and the high prevalence of infectious diseases are key contributors to the growth of the market. In addition, sophisticated healthcare infrastructure and high awareness among the public as well as healthcare professionals have contributed to the large share of the market.

MEA is expected to grow at the fastest CAGR of 8.0% during the forecast period owing to a growing target population, improving infrastructure in the region, high unmet needs, and a large patient pool. Unhealthy lifestyles and growth in the aging population who are susceptible to infectious diseases are leading to the increased occurrence of diseases. Technological infrastructure developments and increased awareness regarding vaccination benefits are also expected to boost the market growth.

Many governments worldwide are increasing their spending on vaccination and demonstrating strong and effective leadership and ownership of immunization programs. Vaccine-preventable diseases are among the major contributors to illness and long-term disabilities in developing nations. However, emerging vaccine manufacturers and increasing funding in developing countries, are expected to fuel growth in developing nations.

Key Companies & Market Share Insights

Significant funding for R&D and new product launches are crucial strategies adopted by leading companies to capture a larger share of the global market. For instance, in August 2021, Vaccines developed by the Serum Institute of India acquired a 50% share in a pharma packing firm, Schott Kaisha. This initiative positions the Serum Institute of India in a joint venture with Schott AG, a specialty glass company based in Germany. Additionally, various initiatives taken by government agencies to develop new vaccines provide opportunities for growth in the market.

For instance, in March 2022, the National Institute of Allergy and Infectious Diseases (NIAID) introduced a clinical trial for the evaluation of three HIV vaccines in their experimental phase. The vaccines are based on a messenger RNA (mRNA) platform, which is a technology previously used in multiple approved Covid-19 vaccines. Some prominent players in the global vaccine delivery devices market include:

• Becton Dickinson & Company

• Bioject Medical Technologies, Inc. (Inovio Pharmaceutical Inc.)

• PharmaJet

• Vaxxas

• Gerresheimer AG

• SCHOTT AG

• Corium International, Inc.

• 3M

Vaccine Delivery Devices Market Report Scope

Global Vaccine Delivery Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global vaccine delivery devices market report on the basis of device, route of administration, and region:

• Device Outlook (Revenue, USD Million, 2018 - 2030)

  • Syringes

  • Jet Injectors

  • Other Devices

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Intradermal Vaccination

  • Intramuscular Vaccination

  • Subcutaneous Vaccination

  • Other Vaccinations

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait